Editorji is a popular short video news and information platform based in India. It was founded in 2018 by Vikram Chandra, one of India’s leading journalists, and has risen to prominence in the digital news space in a relatively short span of time. The platform is primarily designed for mobile devices, with applications available for Android and iOS.

ABOUT US:

about us editorji

Latest Video News: Editorji provides the latest news video headlines, latest videos clip from India and the World. Get all breaking news videos on Entertainment, Business, Coronavirus, Elections, Politics and more.

Latest Video News, Breaking News, Bollywood, Political, Sports, Business News | Editorji

+91 11 4035 6666 / info@editorji.com
3rd floor, Plot B, Khasara no 360, Sultanpur, New Delhi, Delhi 110030
<a title="mail to us" href="mailto:info@editorji.com">Send Feedback</a>
<a title="Contact Us" href="mailto:info@editorji.com">Contact Us</a>

REACH US

Contact for any questions, suggestions, comments, feedback or advertisement on Editorji.com, we are always looking forward to hearing from you.

Contact Us for Feedback, Suggestions and Advertising 

Editorji content is better experienced in our app.

Israel to start human trials on Covid vaccine from Nov 1

The three stages of the human clinical trial of the Israeli vaccine&nbsp;involving over 30,000 volunteers are likely to last till mid-2021

Israel Institute for Biological Research&nbsp;will start human clinical trials of its Covid-19 vaccine candidate Brilife from November 1. The institute has got all necessary approvals from the Ministry of Health and the Helsinki Committee that&nbsp;deals with research approval and human experiments.&nbsp;The three stages of the human clinical trial involving over 30,000 volunteers are likely to last till mid-2021 and if all goes well, the vaccine could be ready for mass use only after that.&nbsp;The first phase of the human trial will include a series of safety tests with the participation of 80 healthy volunteers.

Jerusalem, PTI: Israel Institute for Biological Research (IIBR) will start human clinical trials of its Covid-19 vaccine candidate Brilife from November 1. The institute has got all necessary approvals from the Ministry of Health and the Helsinki Committee, the Israeli Defence Ministry said.
The Helsinki Committee deals with research approval and human experiments.
The committee is mandated to ensure the well being and rights of trial volunteers and to ensure that the experiment is conducted as per the approved medical guidelines and ethics, besides various domestic laws, rules and regulations.
The guidelines are outlined in the Declaration of Helsinki and various relevant international conventions.
The three stages of the human clinical trial involving over 30,000 volunteers are likely to last till mid-2021 and if all goes well, the vaccine could be ready for mass use only after that.
"This is a day of hope for the citizens of Israel, thanks to the IIBR researchers. Just two months ago I received the first bottle of the vaccine. Today we already have 25,000 vaccine doses and are starting the next phase of the test," said Alternate Prime Minister-cum-Defence Minister Benny Gantz.
"I would like to thank the dozens of researchers who work day and night on this national mission in full cooperation with the Ministry of Health. In this complex period, you are the 'commando unit' paving the way for the citizens of Israel. You took on a mission of international and historical importance," Gantz was quoted as saying in an official statement.
"The defence establishment, the Israeli government, and I will continue to provide you with the support and resources required to produce a safe and effective 'blue-and-white' vaccine," he stressed.
"Blue and White" refers to the colours in the Israeli flag, which also happens to be the name of the defence minister's party.
The first phase of the human trial will include a series of safety tests with the participation of 80 healthy volunteers (aged 18-55), designated by Sheba and Hadassah medical centres.
The trial will begin on November 1 with two participants initially. Depending on their responses, the vaccine will then be gradually administered to a total of 80 volunteers -- 40 in each medical centre.
Each volunteer will receive an injection and discharged after a few hours of observation. They will then be monitored over three weeks.

Expect Covid vaccine distribution in mid-2021: WHO

The large-scale global distribution of vaccines against Covid-19 is not expected until mid-2021, the World Health Organization&rsquo;s chief scientist Dr Soumya Swaminathan&nbsp;has said

The large-scale global distribution of vaccines against Covid-19 is not expected until mid-2021, the World Health Organization&rsquo;s chief scientist Dr Soumya Swaminathan told a press briefing on Friday. She said that the second half or the middle of 2021 looks like a realistic bet when "we can start seeing doses actually flowing into countries so that they can start to immunize their populations,&rdquo; Swaminathan said. This timeline is based on the fact that Phase 3 trials of many candidate vaccines are not expected to be concluded until the end of the current year, the WHO&rsquo;s chief scientist added.

mid 2021

Categories